Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Weiss

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group studyK Kelly, J J Crowley, P A Bunn, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Anti-Cancer Drugs|August 1, 1991
Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalatorsK A Havlin, J G Kuhn, J B Craig, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U)G R Weiss, G A Sarosy, T D Shenkenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Cancer Research|August 15, 1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390)C L Arteaga, T D Brown, J G Kuhn, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
New anticancer agentsG R Weiss, H A Burris 3rd, J R Eckardt, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group studyK Kelly, J J Crowley, P A Bunn, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Anti-Cancer Drugs|August 1, 1991
Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalatorsK A Havlin, J G Kuhn, J B Craig, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U)G R Weiss, G A Sarosy, T D Shenkenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Cancer Research|August 15, 1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390)C L Arteaga, T D Brown, J G Kuhn, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
New anticancer agentsG R Weiss, H A Burris 3rd, J R Eckardt, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Pageof 10